🔎 Trials Near Me

Beranda › Kanker (semua jenis) › South Dakota

Uji klinis Kanker (semua jenis) di South Dakota

13 studi untuk Kanker (semua jenis) mencari peserta di lokasi di South Dakota.

Kota di South Dakota

Teks studi resmi (Bahasa Inggris)

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

  • Sanford Children's Hospital ( Site 4015), Sioux Falls
Menerima pesertaFase 1/2
1 Month – 17 Years · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07630974

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • Sanford Cancer Center Oncology Clinic and Pharmacy, Sioux Falls
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT02693535

Connect for Cancer Prevention Study (Connect)

  • Sanford Health, Sioux Falls
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 30 hingga 70 · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04609072

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

  • Sanford Children's Hospital ( Site 3015), Sioux Falls
Menerima pesertaFase 1/2
1 Month – 17 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06941272

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  • Research Site, Sioux Falls
Menerima pesertaFase 3
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07647328

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

  • Sanford Sioux Falls, Sioux Falls
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06163534

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

  • Sanford Cancer Center Oncology Clinic ( Site 0038), Sioux Falls
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07252739

Project: Every Child for Younger Patients With Cancer

  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
Menerima pesertaStudi observasional
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT02402244

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Avera Cancer Institute-Aberdeen, Aberdeen
  • Avera Cancer Institute - Mitchell, Mitchell
  • Avera Cancer Institute at Pierre, Pierre
  • dan 4 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT06580314

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

  • Avera Medical Group Gynecologic Oncology Sioux Falls, Sioux Falls
  • Texas Oncology, P.A. - Tyler, Sioux Falls
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 28 Jul 2026 · NCT07022483

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

  • Sanford Clinical Research, Sioux Falls
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT01042379

Avera Cancer Sequencing and Analytics Protocol (ASAP)

  • Avera Cancer Institute - Aberdeen, Aberdeen
  • Avera Cancer Institute - Mitchell, Mitchell
  • Avera Cancer Institute - Pierre, Pierre
  • dan 2 lainnya
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Mar 2026 · NCT05142033

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

  • Sanford Cancer Center Oncology Clinic, Sioux Falls
  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Nov 2024 · NCT03860883

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.